Mayne Pharma Ownership

Pink Sheets . USA . 
Stock . Mayne Pharma Group
MAYNF Stock  USD 3.10  0.10  3.33%   
Mayne Pharma Group maintains a total of 1.74 Billion outstanding shares. Mayne Pharma Group holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in pink sheets such as Mayne Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Mayne Pharma, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mayne Pharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Mayne Pink Sheet Ownership Analysis

About 23.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mayne Pharma Group recorded a loss per share of 0.03. The entity last dividend was issued on the 18th of January 2023. The firm had 987:937 split on the 30th of June 2016. Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. Mayne Pharma operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange.The quote for Mayne Pharma Group is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Mayne Pharma Group contact Shawn BSc at 61 8 8209 2666 or learn more at https://www.maynepharma.com.

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Mayne Pink Sheet

Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY